RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

The sixth and final season of the award-winning Hulu drama will be a “love letter” to fans who’ve stuck with it through five grueling seasons of often agonizing events, showrunner Yahlin Chang ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a prominent player in the biotechnology industry with a market capitalization of $142 billion and annual revenue of $28.75 billion, has ...

The speaker of the Ekiti State House of Assembly, Adeoye Aribasoye, has called on political and legislative institutions in the country to create more opportunities for women.While lamenting the low ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet – Phase 1 Data Indicate Potential for Use of Once ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Once-Daily Orals and In-Depth Look at Adolescent Pharmacokinetic, Safety and Efficacy Data – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data ...